menu
    • menu
    [{"orgOrder":0,"company":"Neomorph","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.46,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.46,"dosageForm":"","sponsorNew":"Neomorph \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Novo Nordisk"},{"orgOrder":0,"company":"Neomorph","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Molecular Glue Degrader-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neomorph","amount2":1.45,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neomorph \/ Biogen","highestDevelopmentStatusID":"14","companyTruncated":"Neomorph \/ Biogen"}]

    Find Clinical Drug Pipeline Developments & Deals by Neomorph

    Menu

    Neomorph

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neomorph

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Neomorph

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molecular Glue Degrader-based Therapy

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Biogen

                            Deal Size : $1,450.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biogen & Neomorph Announce Collaboration to Discover and Develop Molecular Glue Degraders

                            Details : The collaboration aims to leverage Neomorph's proprietary molecular glue discovery platform to expedite the identification and validation of new small-molecule therapeutics for Alzheimer’s disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 29, 2024

                            Lead Product(s) : Molecular Glue Degrader-based Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Biogen

                            Deal Size : $1,450.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neomorph

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Neomorph

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $1,460.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Neomorph Announces Collaboration with Novo Nordisk to Discover Molecular Glue Degraders

                            Details : The collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 26, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $1,460.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth